KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $209.0 million.

  • AbbVie's Share-based Compensation rose 1546.96% to $209.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $962.0 million, marking a year-over-year increase of 1032.11%. This contributed to the annual value of $911.0 million for FY2024, which is 2195.45% up from last year.
  • AbbVie's Share-based Compensation amounted to $209.0 million in Q3 2025, which was up 1546.96% from $179.0 million recorded in Q2 2025.
  • In the past 5 years, AbbVie's Share-based Compensation ranged from a high of $410.0 million in Q1 2025 and a low of $107.0 million during Q2 2022
  • Moreover, its 5-year median value for Share-based Compensation was $179.0 million (2023), whereas its average is $201.0 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 3270.44% in 2022, then surged by 6728.97% in 2023.
  • AbbVie's Share-based Compensation (Quarter) stood at $129.0 million in 2021, then grew by 2.33% to $132.0 million in 2022, then dropped by 5.3% to $125.0 million in 2023, then surged by 31.2% to $164.0 million in 2024, then grew by 27.44% to $209.0 million in 2025.
  • Its Share-based Compensation stands at $209.0 million for Q3 2025, versus $179.0 million for Q2 2025 and $410.0 million for Q1 2025.